| Description | GS-9901 is a selective, orally active and potent PI3Kδ inhibitor (IC50: 1 nM) for the study of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. |
| In vivo | 在已建立胶原诱导性关节炎（CIA）的雌性 Lewis 大鼠中，GS-9901（0.3 mg/kg、1 mg/kg 和 3mg/kg；口服，每天两次，连续7天，从第二次胶原免疫后的第 10 天开始）能够显著减少踝关节肿胀[1]。 |
| Target activity | PI3Kδ:1 nM |
| molecular weight | 477.88 |
| Molecular formula | C22H17ClFN9O |
| CAS | 1640247-87-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 120 mg/mL (251.11 mM), Sonication is recommended. |
| References | 1. Patel L, et al. Discovery of Orally Efficacious Phosphoinositide 3-Kinase δ Inhibitors with Improved Metabolic Stability. J Med Chem. 2016 Oct 13;59(19):9228-9242. |